BIOMAT Database Logo BIOMAT Database Logo

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. 1997

B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Department of Orthopedics, Sahlgrenska-Ostra University Hospital, Göteborg, Sweden.

BACKGROUND Patients who undergo total hip replacement have a high risk of thromboembolic complications. Recombinant hirudin (desirudin), a specific inhibitor of thrombin, represents a new development in antithrombotic therapy. We compared the efficacy and safety of desirudin with those of a low-molecular-weight heparin (enoxaparin) for the prevention of thromboembolic complications in patients undergoing primary total hip replacement. METHODS Both treatments, which were assigned in a randomized, double-blind manner, were started preoperatively: enoxaparin on the evening before surgery, and desirudin within 30 minutes before the start of surgery. The dose of desirudin was 15 mg subcutaneously twice daily, and the dose of enoxaparin was 40 mg subcutaneously once daily. The duration of treatment was 8 to 12 days. Deep-vein thrombosis was verified by bilateral venography performed at the end of the treatment period or earlier, if there were clinical signs of deep-vein thrombosis. RESULTS At 31 centers in 10 European countries, 2079 eligible patients were randomly assigned to receive desirudin or enoxaparin. A total of 1587 patients were included in the primary analysis of efficacy. In the desirudin group, as compared with the enoxaparin group, there was a significantly lower rate of proximal deep-vein thrombosis (4.5 vs. 7.5 percent, P=0.01; relative reduction in risk, 40.3 percent) and a lower overall rate of deep-vein thrombosis (18.4 vs. 25.5 percent, P=0.001; relative reduction in risk, 28.0 percent). The safety profiles were similar in the two treatment groups. CONCLUSIONS When administered 30 minutes before total hip replacement surgery, desirudin is more effective than enoxaparin in preventing deep-vein thrombosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006629 Hirudins Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN. Hirudin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
March 1998, The New England journal of medicine,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement.
April 1997, Canadian journal of surgery. Journal canadien de chirurgie,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
September 1992, The British journal of surgery,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Thromboembolic complications after total hip replacement.
January 2002, International orthopaedics,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
October 2002, Archives of internal medicine,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.
November 1988, The British journal of surgery,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
August 1994, Thrombosis and haemostasis,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement.
January 1990, Acta chirurgica Scandinavica,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
September 1996, The New England journal of medicine,
B I Eriksson, and P Wille-Jørgensen, and P Kälebo, and P Mouret, and N Rosencher, and P Bösch, and M Baur, and S Ekman, and D Bach, and S Lindbratt, and P Close
Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.
April 1991, The Journal of bone and joint surgery. American volume,
Copied contents to your clipboard!